HK1124764A1 - Binding proteins specific for insulin-like growth factors and uses thereof - Google Patents
Binding proteins specific for insulin-like growth factors and uses thereofInfo
- Publication number
- HK1124764A1 HK1124764A1 HK09102193.2A HK09102193A HK1124764A1 HK 1124764 A1 HK1124764 A1 HK 1124764A1 HK 09102193 A HK09102193 A HK 09102193A HK 1124764 A1 HK1124764 A1 HK 1124764A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- insulin
- growth factors
- binding proteins
- proteins specific
- specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75008505P | 2005-12-13 | 2005-12-13 | |
US75077205P | 2005-12-14 | 2005-12-14 | |
US77474706P | 2006-02-17 | 2006-02-17 | |
US80818306P | 2006-05-24 | 2006-05-24 | |
PCT/US2006/047059 WO2007070432A2 (en) | 2005-12-13 | 2006-12-08 | Binding proteins specific for insulin-like growth factors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1124764A1 true HK1124764A1 (en) | 2009-07-24 |
Family
ID=38110454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09102193.2A HK1124764A1 (en) | 2005-12-13 | 2009-03-06 | Binding proteins specific for insulin-like growth factors and uses thereof |
Country Status (26)
Country | Link |
---|---|
US (4) | US7939637B2 (zh) |
EP (2) | EP2404616A3 (zh) |
JP (1) | JP5302007B2 (zh) |
KR (1) | KR101372690B1 (zh) |
CN (1) | CN105753983A (zh) |
AR (1) | AR058322A1 (zh) |
AT (1) | ATE552853T1 (zh) |
AU (1) | AU2006326649B2 (zh) |
BR (1) | BRPI0619786A2 (zh) |
CA (1) | CA2633956C (zh) |
CY (1) | CY1112876T1 (zh) |
DK (1) | DK1979001T3 (zh) |
EC (1) | ECSP088616A (zh) |
ES (1) | ES2385054T3 (zh) |
HK (1) | HK1124764A1 (zh) |
HR (1) | HRP20120421T1 (zh) |
IL (2) | IL191718A (zh) |
MX (1) | MX2008007688A (zh) |
NO (1) | NO20082634L (zh) |
PL (1) | PL1979001T3 (zh) |
PT (1) | PT1979001E (zh) |
RS (1) | RS52357B (zh) |
RU (2) | RU2492185C2 (zh) |
TW (1) | TW200801040A (zh) |
UY (1) | UY30002A1 (zh) |
WO (1) | WO2007070432A2 (zh) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2527871T3 (es) * | 2003-05-01 | 2015-02-02 | Imclone Llc | Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana |
CA2678008C (en) * | 2005-06-17 | 2013-07-30 | Imclone Systems Incorporated | Methods of treating a secondary bone tumor with anti-pdgfralpha antibodies |
CN101484587B (zh) * | 2006-02-03 | 2014-02-12 | 英克隆有限责任公司 | Igf-ir拮抗剂作为辅药用于前列腺癌的治疗 |
MX2009000476A (es) | 2006-07-14 | 2009-01-28 | Ac Immune Sa | Anticuerpo humanizado contra beta amiloide. |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
WO2008152422A2 (en) * | 2007-06-12 | 2008-12-18 | Astrazeneca Ab | Binding proteins specific for insulin-like growth factors and uses thereof-909 |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
PE20090368A1 (es) * | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
WO2009006336A1 (en) * | 2007-06-28 | 2009-01-08 | Sylgen Laboratories, Inc. | Compositions and methods for inhibiting angiogenesis and tumorigenesis |
WO2009048539A2 (en) | 2007-10-05 | 2009-04-16 | Genentech, Inc. | Monoclonal antibody |
CN102076355B (zh) * | 2008-04-29 | 2014-05-07 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
JP5734180B2 (ja) * | 2008-05-09 | 2015-06-17 | ダイアックス コーポレーション | Igf−ii/igf−iie結合タンパク質 |
EP3002299A1 (en) | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
US9109026B2 (en) | 2008-06-03 | 2015-08-18 | Abbvie, Inc. | Dual variable domain immunoglobulins and uses thereof |
KR20110031369A (ko) | 2008-07-08 | 2011-03-25 | 아보트 러보러터리즈 | 프로스타글란딘 e2 이원 가변 도메인 면역글로불린 및 이의 용도 |
EP2349329A4 (en) | 2008-10-14 | 2012-10-31 | Dyax Corp | USE OF IGF-II / IGF-II BINDING FOR THE TREATMENT AND PREVENTION OF SYSTEMIC SCLEROSIS ASSOCIATED WITH LUNG FIBROSIS |
CZ2008697A3 (cs) * | 2008-11-03 | 2010-04-28 | Univerzita Karlova v Praze, 1. Lékarská fakulta | Kombinace monoklonálních protilátek nebo jejich Fab fragmentu pro použití jako lécivo a farmaceutický prípravek tyto protilátky nebo jejich Fab fragmenty obsahující |
AU2009312731B2 (en) | 2008-11-10 | 2012-12-20 | Novartis Ag | Antibodies to modified human IGF-1/E peptides |
NZ592151A (en) * | 2008-12-12 | 2012-10-26 | Boehringer Ingelheim Int | Anti-igf antibodies |
US20100316639A1 (en) | 2009-06-16 | 2010-12-16 | Genentech, Inc. | Biomarkers for igf-1r inhibitor therapy |
AU2010282508B2 (en) * | 2009-08-13 | 2015-05-28 | Crystal Bioscience Inc. | Transgenic animal for production of antibodies having minimal CDRs |
NZ598929A (en) * | 2009-09-01 | 2014-05-30 | Abbvie Inc | Dual variable domain immunoglobulins and uses thereof |
CN102666875A (zh) * | 2009-10-15 | 2012-09-12 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
KR101713365B1 (ko) | 2010-07-30 | 2017-03-08 | 에이씨 이뮨 에스.에이. | 안전하고 기능적인 인간화 항 베타-아밀로이드 항체 |
BR112013002578A2 (pt) | 2010-08-03 | 2019-05-14 | Abbvie Inc. | imunoglobinas de domínio variável duplo e usos das mesmas |
AU2011293253B2 (en) | 2010-08-26 | 2014-12-11 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
AU2011329067A1 (en) * | 2010-11-16 | 2013-05-30 | Medimmune, Llc | Regimens for treatments using anti-IGF antibodies |
AU2012212075A1 (en) * | 2011-02-02 | 2013-07-18 | Amgen Inc. | Methods and compositons relating to inhibition of IGF-1R |
EP3138581B1 (en) | 2011-03-17 | 2019-01-02 | The University of Birmingham | Re-directed immunotherapy |
US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
US9127056B2 (en) | 2011-10-17 | 2015-09-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor II (IGF-II) |
TW201333035A (zh) | 2011-12-30 | 2013-08-16 | Abbvie Inc | 針對il-13及/或il-17之雙特異性結合蛋白 |
MY194330A (en) | 2012-11-01 | 2022-11-28 | Abbvie Inc | Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
KR20150088869A (ko) * | 2012-11-29 | 2015-08-03 | 바이엘 헬스케어 엘엘씨 | 활성화 단백질 C(aPC)에 대한 모노클로날 항체 |
US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
WO2014150840A1 (en) * | 2013-03-15 | 2014-09-25 | Medimmune, Llc | Methods of treating breast cancer |
WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
CN105324396A (zh) | 2013-03-15 | 2016-02-10 | 艾伯维公司 | 针对IL-1β和/或IL-17的双重特异性结合蛋白 |
AU2014318017B2 (en) | 2013-09-05 | 2020-02-06 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
JP2017502025A (ja) * | 2013-12-19 | 2017-01-19 | メディミューン,エルエルシー | 肉腫を治療するための組成物および方法 |
EP3143404B1 (en) | 2014-05-16 | 2018-08-29 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
WO2016208696A1 (ja) | 2015-06-24 | 2016-12-29 | Jcrファーマ株式会社 | Bdnfを含む融合蛋白質 |
SG11201908328XA (en) | 2017-03-14 | 2019-10-30 | Amgen Inc | Control of total afucosylated glycoforms of antibodies produced in cell culture |
KR20200135781A (ko) | 2018-03-26 | 2020-12-03 | 암젠 인크 | 세포 배양에서 생산된 항체의 총 비푸코실화 당형태 |
KR20210105890A (ko) | 2018-12-17 | 2021-08-27 | 레비토프 리미티드 | 트윈 면역 세포 인게이저 |
WO2020160560A2 (en) * | 2019-02-01 | 2020-08-06 | Novarock Biotherapeutics, Ltd. | Anti-claudin 18 antibodies and methods of use thereof |
CA3152547A1 (en) | 2019-09-26 | 2021-04-01 | Amgen Inc. | Methods of producing antibody compositions |
WO2021247892A1 (en) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
WO2022081824A1 (en) | 2020-10-15 | 2022-04-21 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
AU2022289365A1 (en) | 2021-06-07 | 2023-12-14 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
WO2023059607A1 (en) | 2021-10-05 | 2023-04-13 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
CN114031685B (zh) * | 2022-01-10 | 2022-03-25 | 中国人民解放军军事科学院军事医学研究院 | 一种全人源抗新冠病毒中和抗体zw2g10及应用 |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3180193A (en) | 1963-02-25 | 1965-04-27 | Benedict David | Machines for cutting lengths of strip material |
GB1047304A (zh) | 1963-07-05 | |||
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
ATE12348T1 (de) | 1980-11-10 | 1985-04-15 | Gersonde Klaus Prof Dr | Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens. |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
JPS58118008A (ja) | 1982-01-06 | 1983-07-13 | Nec Corp | デ−タ処理装置 |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
JPS58166633A (ja) | 1982-03-29 | 1983-10-01 | Toshiba Corp | 有機溶媒電池用正極 |
JPS58166634A (ja) | 1982-03-29 | 1983-10-01 | Toshiba Corp | 有機溶媒電池用正極 |
EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
ATE59966T1 (de) | 1983-09-26 | 1991-02-15 | Ehrenfeld Udo | Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr. |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
JPS62170639A (ja) | 1986-01-22 | 1987-07-27 | 株式会社システムメンテナンス | 防蟻板の取付け工法 |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
JP3070763B2 (ja) | 1989-08-09 | 2000-07-31 | ロメッド インコーポレイティド | テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識 |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
CA2058041A1 (en) | 1990-06-27 | 1991-12-28 | Katsuichi Sakano | Anti-igf-ii monoclonal antibody |
FR2664073A1 (fr) | 1990-06-29 | 1992-01-03 | Thomson Csf | Moyens de marquage d'objets, procede de realisation et dispositif de lecture. |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
ATE352612T1 (de) | 1990-08-29 | 2007-02-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
AU4541093A (en) | 1992-06-18 | 1994-01-24 | Genpharm International, Inc. | Methods for producing transgenic non-human animals harboring a yeast artificial chromosome |
AU675661B2 (en) | 1992-07-24 | 1997-02-13 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
UA58494C2 (uk) | 1995-06-07 | 2003-08-15 | Зенека Лімітед | Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну |
KR100308764B1 (ko) | 1995-08-29 | 2001-12-17 | 마나배게이사꾸 | 키메라동물및그의제작법 |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
KR100489174B1 (ko) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-아닐리노퀴나졸린유도체 |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
US6417330B1 (en) * | 1998-06-01 | 2002-07-09 | Celtrix Pharmaceuticals, Inc. | Insulin-like growth factor binding protein variants |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
US20050277627A1 (en) | 2000-07-07 | 2005-12-15 | Arnould Jean C | Colchinol derivatives as vascular damaging agents |
KR20030022264A (ko) | 2000-07-07 | 2003-03-15 | 앤지오젠 파마슈티칼스 리미티드 | 신생 혈관 형성 억제제인 콜치놀 유도체 |
PT1399483E (pt) * | 2001-01-05 | 2010-07-20 | Pfizer | Anticorpos contra o receptor do factor i de crescimento tipo insulina |
AU2002353017A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Discovery of therapeutic products |
AU2003231554A1 (en) * | 2002-04-30 | 2003-11-17 | Kyowa Hakko Kogyo Co., Ltd. | Antibody to human insulin-like growth factor |
ES2527871T3 (es) * | 2003-05-01 | 2015-02-02 | Imclone Llc | Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana |
US20060263362A1 (en) * | 2003-08-21 | 2006-11-23 | Atsushi Ochiai | Cancer metastasis inhibitor |
US7498415B2 (en) | 2003-09-24 | 2009-03-03 | Kyowa Hakko Kogyo Co., Ltd. | Recombinant antibody against human insulin-like growth factor |
JPWO2005027970A1 (ja) | 2003-09-24 | 2007-11-15 | 協和醗酵工業株式会社 | 癌治療用医薬 |
CA2618920C (en) | 2005-08-17 | 2015-03-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Human monoclonal antibodies that specifically bind igf-ii |
JP6071725B2 (ja) | 2013-04-23 | 2017-02-01 | カルソニックカンセイ株式会社 | 電気自動車の駆動力制御装置 |
US11284893B2 (en) | 2019-04-02 | 2022-03-29 | Covidien Lp | Stapling device with articulating tool assembly |
-
2006
- 2006-12-08 CN CN201510424537.5A patent/CN105753983A/zh not_active Withdrawn
- 2006-12-08 CA CA2633956A patent/CA2633956C/en not_active Expired - Fee Related
- 2006-12-08 MX MX2008007688A patent/MX2008007688A/es active IP Right Grant
- 2006-12-08 AT AT06848597T patent/ATE552853T1/de active
- 2006-12-08 PT PT06848597T patent/PT1979001E/pt unknown
- 2006-12-08 US US11/608,705 patent/US7939637B2/en not_active Expired - Fee Related
- 2006-12-08 KR KR1020087016918A patent/KR101372690B1/ko not_active IP Right Cessation
- 2006-12-08 EP EP20110175663 patent/EP2404616A3/en not_active Withdrawn
- 2006-12-08 RS RS20120260A patent/RS52357B/en unknown
- 2006-12-08 BR BRPI0619786-8A patent/BRPI0619786A2/pt not_active IP Right Cessation
- 2006-12-08 WO PCT/US2006/047059 patent/WO2007070432A2/en active Application Filing
- 2006-12-08 PL PL06848597T patent/PL1979001T3/pl unknown
- 2006-12-08 RU RU2008128355/10A patent/RU2492185C2/ru not_active IP Right Cessation
- 2006-12-08 EP EP06848597A patent/EP1979001B1/en active Active
- 2006-12-08 DK DK06848597.8T patent/DK1979001T3/da active
- 2006-12-08 ES ES06848597T patent/ES2385054T3/es active Active
- 2006-12-08 AU AU2006326649A patent/AU2006326649B2/en not_active Ceased
- 2006-12-08 JP JP2008545698A patent/JP5302007B2/ja not_active Expired - Fee Related
- 2006-12-11 UY UY30002A patent/UY30002A1/es not_active Application Discontinuation
- 2006-12-12 AR ARP060105469A patent/AR058322A1/es unknown
- 2006-12-13 TW TW095146733A patent/TW200801040A/zh unknown
-
2008
- 2008-05-26 IL IL191718A patent/IL191718A/en not_active IP Right Cessation
- 2008-06-04 NO NO20082634A patent/NO20082634L/no not_active Application Discontinuation
- 2008-07-09 EC EC2008008616A patent/ECSP088616A/es unknown
-
2009
- 2009-03-06 HK HK09102193.2A patent/HK1124764A1/xx not_active IP Right Cessation
-
2011
- 2011-04-01 US US13/078,480 patent/US8410058B2/en not_active Expired - Fee Related
-
2012
- 2012-05-16 HR HRP20120421TT patent/HRP20120421T1/hr unknown
- 2012-07-11 CY CY20121100620T patent/CY1112876T1/el unknown
-
2013
- 2013-03-14 US US13/803,711 patent/US9181336B2/en not_active Expired - Fee Related
- 2013-05-31 RU RU2013125306/10A patent/RU2549703C2/ru not_active IP Right Cessation
-
2014
- 2014-09-22 IL IL234798A patent/IL234798A/en not_active IP Right Cessation
-
2015
- 2015-10-06 US US14/875,812 patent/US9796779B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1124764A1 (en) | Binding proteins specific for insulin-like growth factors and uses thereof | |
HK1256740A1 (zh) | 白介素-13結合蛋白 | |
IL228793A0 (en) | 40p/12–il binding proteins | |
IL195038A0 (en) | Hepatocyte growth factor binding proteins | |
IL198872A0 (en) | Igf-1r binding proteins and compositions containing the same | |
IL181005A0 (en) | Polypeptide comprising binding domains | |
HK1121470A1 (en) | Binding polypeptides and uses thereof | |
IL195037A0 (en) | Binding proteins that bind hepatocyte growth factor | |
EP1789451A4 (en) | TIE COMPLEX BINDING PROTEINS | |
IL188345A (en) | A binding protein specific to cd37 | |
EP1957094A4 (en) | CALCIUM-BINDING PEPTIDES | |
PL1838341T3 (pl) | Kompozycja szczepionki obejmująca białko wiążące fibronektynę lub peptyd wiążący fibronektynę | |
EP2193145A4 (en) | COMPOSITIONS AND METHODS COMPRISING BINDING PROTEINS FOR ADALIMUMAB | |
GB2449354B (en) | Binding protein | |
ZA200801389B (en) | II-6 Binding proteins | |
EP2227242A4 (en) | BONE MORPHOGUE PROTEIN BINDING SPEPTIDE | |
ZA200804925B (en) | Binding proteins specific for insulin-like growth factors and uses thereof | |
EP1915391A4 (en) | SRA-BINDING PROTEIN | |
GB0511799D0 (en) | Protein binding ligands | |
GB0522113D0 (en) | vWFA-domain containing proteins | |
GB0511861D0 (en) | Proteins | |
AU2005907268A0 (en) | SRA Binding Protein | |
AU2005903903A0 (en) | SRA Binding Protein | |
GB0423299D0 (en) | Furin domain-containing proteins | |
AU2006903090A0 (en) | SRA Binding Protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20181208 |